Acute Myeloid Leukemia, Childhood Clinical Trial
Official title:
A Prospective Multicenter Clinical Trial of Treatment Strategy Based on MRD Level After 2 Initial Courses of Chemotherapy in Children and Young Adults With Acute Myeloid Leukemia
Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control parameter for the optimal therapy tactics. Patients with initially high-risk group and those with high MRD after 2 initial courses of chemotherapy will be assigned to the allogenic transplantation of the hematopoietic stem cells from Human Leucocyte Antigen (HLA) matched or haploidentical family donors.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | January 2025 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 18 Years |
Eligibility | Inclusion Criteria: 1. de novo acute myeloid leukemia 2. signed informed consent Exclusion Criteria: diagnosis of: Fanconi anemia, acute promyelocytic leukemia, MDS, JMML, AML as secondary malignancy, Dawn syndrome. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Regional Children's Clinical Hospital ? 1 | Ekaterinburg | Sverdlovsk Oblast |
Russian Federation | Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology | Moscow |
Lead Sponsor | Collaborator |
---|---|
Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Physicians, Innovations, Science for Children Fund |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | relapse-free survival (RFS) | relapse-free survival from date of diagnosis till date of relapse, or date of death (whichever comes first) or date of last follow up | 1 year | |
Secondary | overall survival (OS) | 1 year | ||
Secondary | event-free survival (EFS) | Event=relapse/nonresponse, death or second malignancy | 2 years | |
Secondary | The proportion of of patients with severe adverse effects | The proportion of of patients with severe adverse effects of therapy according to CTCAE (ver 4.3) | 6 months | |
Secondary | The proportion of of patients with severe infections | The proportion of of patients with severe infections: number of episodes, grade, after each course of chemotherapy | 1 month | |
Secondary | The proportion of of patients with severe cardiotoxicity | The proportion of of patients with severe cardiotoxicity: number of episodes and %EF by echocardiogam | 1 year | |
Secondary | MRD dynamic | MRD (IFT and/or PCR) dynamic between check-points | 1 months | |
Secondary | MRD specificity and sensitivity | MRD specificity and sensitivity in relapse prognosis | 1, 2, 3 months | |
Secondary | Cumulative incidence of relapse | competing event - death in CR | 6 months, 1 year | |
Secondary | Cumulative incidence of transplant-related mortality | for transplanted patients | 6 months after HSCT | |
Secondary | Cumulative incidence of aGvHD II-IV grade | for transplanted patients | 100 days after HSCT | |
Secondary | Cumulative incidence of cGvHD | for transplanted patients | 1 year after HSCT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05519384 -
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
|
Early Phase 1 |